<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423189</url>
  </required_header>
  <id_info>
    <org_study_id>LUV</org_study_id>
    <nct_id>NCT00423189</nct_id>
  </id_info>
  <brief_title>Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration</brief_title>
  <official_title>Lucentis Utilizing Visudyne (LUV Trial)-- Reduced Fluence Photodynamic Therapy With Visudyne Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David M. Brown, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Greater Houston Retina Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PDT/Lucentis trial will be a Phase IV comparative trial comparing the use of combination&#xD;
      therapy with ITV ranibizumab and verteporfin PDT to ITV ranibizumab alone in patients with&#xD;
      exudative AMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PDT/Lucentis trial will be a Phase IV comparative trial comparing the use of combination&#xD;
      therapy with ITV ranibizumab and verteporfin PDT to ITV ranibizumab alone in patients with&#xD;
      exudative AMD. Patients will be randomized to one of three groups. All patients will receive&#xD;
      three consecutive monthly treatments with ITV ranibizumab. Patients randomized to group I&#xD;
      will receive only ITV ranibizumab. Patients randomized to group II will also receive one&#xD;
      treatment with reduced fluence (20% fluence) verteporfin PDT at day 0. Patients randomized to&#xD;
      group III will also receive one treatment with reduced fluence (40% fluence) vPDT. All&#xD;
      patients will also be evaluated for possible retreatment with ranibizumab according to&#xD;
      established criteria. Thirty patients (ten per group) will be recruited from one U.S. sites&#xD;
      in a 6-month period. Randomization will occur at the time of entry into the study. Follow-up&#xD;
      will continue until month 12 (from day 0) in all subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy&#xD;
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected ETDRS Visual Acuity at 6 Months and 12 Months Only Time Points (Gain or Loss of &gt;15 Letters at 12 Months)</measure>
    <time_frame>1 Year</time_frame>
    <description>Visual Acuity was measured by ETDRS by certified refractionists in certified lanes at 12 months. Visual Acuity was not measured by ETDRS at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Intravitreal Injections With Ranibizumab Needed by Patients at 12 Months</measure>
    <time_frame>1 Year</time_frame>
    <description>Number of intravitreal injections with ranibizumab needed by patients at 12 months was not determined due to lack of efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT 3 Macular Thickness Improvement (Baseline-1month, 2months, 3months, 6months &amp;12 Months)</measure>
    <time_frame>1 Year</time_frame>
    <description>OCT 3 macular thickness improvement at Baseline-1month, 2months, 3months, 6months &amp;12 months was not determined due to lack of efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Choroidal Perfusion as Assessed by ICG Angiography at 1, 2, 3, 6, and 12 Months</measure>
    <time_frame>1 Year</time_frame>
    <description>Choroidal perfusion as assessed by ICG angiography at 1, 2, 3, 6, and 12 months was not determined due to lack of efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Combination Therapy With Verteporfin PDT and ITV Ranibizumab</measure>
    <time_frame>1 Year</time_frame>
    <description>Safety of combination therapy with verteporfin PDT and ITV ranibizumab was not determined due to lack of efficacy.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>drug - intravitreal ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40% fluence PDT/procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20% fluence photodynamic therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab (Lucentis)</intervention_name>
    <description>as needed, one intravitreal injection of 0.50mg ranibizumab</description>
    <arm_group_label>20% fluence photodynamic therapy</arm_group_label>
    <arm_group_label>40% fluence PDT/procedure</arm_group_label>
    <arm_group_label>Ranibizumab only</arm_group_label>
    <other_name>PDT</other_name>
    <other_name>Photodynamic Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5mg ranibizumab</intervention_name>
    <description>as needed, one intravitreal injection of 0.50mg ranibizumab</description>
    <arm_group_label>20% fluence photodynamic therapy</arm_group_label>
    <arm_group_label>40% fluence PDT/procedure</arm_group_label>
    <arm_group_label>Ranibizumab only</arm_group_label>
    <other_name>lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study&#xD;
&#xD;
          -  Age &gt; 55 years&#xD;
&#xD;
          -  Subfoveal neovascular membrane confirmed by fluorescein angiography and or ICG&#xD;
&#xD;
          -  Visual acuity not better than 20/32 and not worse than 20/320 by ETDRS refraction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous vitrectomy in study eye (posterior or anterior associated with vitreous&#xD;
             loss in cataract surgery)&#xD;
&#xD;
          -  Intracapsular cataract extraction (posterior capsule needs to be present)&#xD;
&#xD;
          -  Previous treatment with ranibizumab&#xD;
&#xD;
          -  Previous treatment with pegaptanib&#xD;
&#xD;
          -  Previous treatment with ITV triamcinolone&#xD;
&#xD;
          -  Any previous treatment with photodynamic therapy&#xD;
&#xD;
          -  Previous history of retinal detachment in study eye&#xD;
&#xD;
          -  Any previous radiation treatments to head/ neck&#xD;
&#xD;
          -  Significant cardiovascular disease or cancer that would prevent follow-up visits or&#xD;
             completion of the 12 month study&#xD;
&#xD;
          -  Prior enrollment in any study for AMD in the study eye&#xD;
&#xD;
          -  Participation in another simultaneous medical investigator or trial&#xD;
&#xD;
          -  Ocular disorders in the study eye that may confound interpretation of study results,&#xD;
             including retinal detachment or macular hole.&#xD;
&#xD;
          -  Concurrent disease in the study eye that could compromise visual acuity or require&#xD;
             medical or surgical intervention during the study period&#xD;
&#xD;
          -  Aphakia or absence of the posterior capsule in the study eye&#xD;
&#xD;
          -  Previous violation of the posterior capsule is also excluded unless it occurred as a&#xD;
             result of YAG laser posterior capsulotomy in association with prior, posterior chamber&#xD;
             intraocular lens implantation&#xD;
&#xD;
          -  History of idiopathic or autoimmune uveitis in either eye&#xD;
&#xD;
          -  Significant structural damage to the center of the macula in the study eye likely to&#xD;
             preclude improvement in visual acuity following the resolution of macular edema,&#xD;
             including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser&#xD;
             scar(s)&#xD;
&#xD;
          -  Vitreomacular traction or epiretinal membrane in the study eye evident&#xD;
             biomicroscopically or by OCT&#xD;
&#xD;
          -  Ocular inflammation (including trace or above) in the study eye&#xD;
&#xD;
          -  Uncontrolled glaucoma (defined as intraocular pressure ≥30 mm Hg despite treatment&#xD;
             with anti- medications) or previous filtration surgery in the study eye&#xD;
&#xD;
          -  Infectious blepharitis, keratitis, scleritis, or conjunctivitis (in either eye) or&#xD;
             current treatment for serious systemic infection&#xD;
&#xD;
          -  Spherical equivalent of the refractive error in the study eye of more than -8 diopters&#xD;
             myopia (For patients who have had refractive or cataract surgery in the study eye,&#xD;
             pre-operative spherical equivalent refractive error of more than -8 diopters myopia is&#xD;
             not allowed)&#xD;
&#xD;
        Systemic Conditions&#xD;
&#xD;
          -  Uncontrolled Blood pressure exceeding diastolic pressure of 100 mm Hg (sitting) during&#xD;
             the screening period&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Renal failure requiring dialysis or renal transplant&#xD;
&#xD;
          -  Premenopausal women not using adequate contraception&#xD;
&#xD;
          -  Previous participation in other studies of investigational drugs (excluding vitamins&#xD;
             and minerals) within 3 months preceding Day 0&#xD;
&#xD;
          -  History of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             other findings giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use an investigational drug, might affect interpretation of the&#xD;
             results of the study, or render the subject at high risk from treatment complications&#xD;
&#xD;
          -  INR ≥ 3.0 (e.g. due to current treatment with warfarin). The use of aspirin is not an&#xD;
             exclusion.&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  History of allergy to fluorescein, not amenable to treatment&#xD;
&#xD;
          -  History of allergy to shellfish&#xD;
&#xD;
          -  History of allergy to intravenous iodine&#xD;
&#xD;
          -  History of allergy to indocyanine green&#xD;
&#xD;
          -  Inability to obtain fundus photographs or angiograms of sufficient quality to be&#xD;
             analyzed and graded by the central reading center&#xD;
&#xD;
          -  Inability to comply with study or follow up procedures&#xD;
&#xD;
          -  History of allergy to humanized antibodies or any component of the ranibizumab&#xD;
             formulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Brown, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vitreoretinal Consultants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vitreoretinal Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.houstonretina.com</url>
    <description>GreaterHRR website</description>
  </link>
  <reference>
    <citation>Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44.</citation>
    <PMID>17021319</PMID>
  </reference>
  <reference>
    <citation>Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.</citation>
    <PMID>17021318</PMID>
  </reference>
  <reference>
    <citation>Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci. 2006 Jan;47(1):371-6.</citation>
    <PMID>16384987</PMID>
  </reference>
  <reference>
    <citation>Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC; Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005 Apr;123(4):448-57.</citation>
    <PMID>15824216</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <results_first_submitted>October 17, 2012</results_first_submitted>
  <results_first_submitted_qc>February 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2016</results_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Greater Houston Retina Research</investigator_affiliation>
    <investigator_full_name>David M. Brown, M.D.</investigator_full_name>
    <investigator_title>Director of Research</investigator_title>
  </responsible_party>
  <keyword>LUV</keyword>
  <keyword>Lucentis</keyword>
  <keyword>Visudyne</keyword>
  <keyword>PDT</keyword>
  <keyword>AMD</keyword>
  <keyword>ARMD</keyword>
  <keyword>Age</keyword>
  <keyword>Related</keyword>
  <keyword>Macular</keyword>
  <keyword>Degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>7 patients, over a 12 month period were followed after receiving treatment of either decreased fluence(2 different fluences) and 0.5mg ranibizumab, as compared to monotherapy of 0.5mg ranibizumab at a single site</recruitment_details>
      <pre_assignment_details>patients that were considered to have recalcitrant wet age related macular degeneration were recruited for this trial</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab Only</title>
          <description>drug - intravitreal ranibizumab</description>
        </group>
        <group group_id="P2">
          <title>Ranibizumab and 40% Fluence PDT(Procedure)</title>
          <description>40% fluence photodynamic therapy - procedure</description>
        </group>
        <group group_id="P3">
          <title>Ranibizumab and 20% Fluence PDT(Procedure)</title>
          <description>20% fluence photodynamic therapy - procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>drug - intravitreal ranibizumab</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>40% fluence photodynamic therapy - procedure</description>
        </group>
        <group group_id="B3">
          <title>Arm 3</title>
          <description>20% fluence photodynamic therapy - procedure</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="3"/>
                    <measurement group_id="B2" value="78" spread="7"/>
                    <measurement group_id="B3" value="67" spread="5"/>
                    <measurement group_id="B4" value="72" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="03"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best-corrected ETDRS Visual Acuity at 6 Months and 12 Months Only Time Points (Gain or Loss of &gt;15 Letters at 12 Months)</title>
        <description>Visual Acuity was measured by ETDRS by certified refractionists in certified lanes at 12 months. Visual Acuity was not measured by ETDRS at 6 months.</description>
        <time_frame>1 Year</time_frame>
        <population>As per subjects participated</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Only</title>
            <description>IVT Ranibizumab only</description>
          </group>
          <group group_id="O2">
            <title>40% Fluence PDT/Ranibizumab</title>
            <description>40% Fluence PDT WITH ivt Ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>20% Fluence PDT/Ranibizumab</title>
            <description>20% Fluence PDT with IVT Ranibizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Best-corrected ETDRS Visual Acuity at 6 Months and 12 Months Only Time Points (Gain or Loss of &gt;15 Letters at 12 Months)</title>
          <description>Visual Acuity was measured by ETDRS by certified refractionists in certified lanes at 12 months. Visual Acuity was not measured by ETDRS at 6 months.</description>
          <population>As per subjects participated</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Intravitreal Injections With Ranibizumab Needed by Patients at 12 Months</title>
        <description>Number of intravitreal injections with ranibizumab needed by patients at 12 months was not determined due to lack of efficacy.</description>
        <time_frame>1 Year</time_frame>
        <population>not determined due to lack of efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Only</title>
            <description>drug - intravitreal ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>40% Fluence Photodynamic Therapy Combined With Ranibizumab</title>
            <description>40% fluence photodynamic therapy combined with ranibizumab- procedure</description>
          </group>
          <group group_id="O3">
            <title>20% Fluence Photodynamic Therapy Combined With Ranibizumab</title>
            <description>20% fluence photodynamic therapy combined with ranibizumab- procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Intravitreal Injections With Ranibizumab Needed by Patients at 12 Months</title>
          <description>Number of intravitreal injections with ranibizumab needed by patients at 12 months was not determined due to lack of efficacy.</description>
          <population>not determined due to lack of efficacy</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OCT 3 Macular Thickness Improvement (Baseline-1month, 2months, 3months, 6months &amp;12 Months)</title>
        <description>OCT 3 macular thickness improvement at Baseline-1month, 2months, 3months, 6months &amp;12 months was not determined due to lack of efficacy.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Only</title>
            <description>drug - intravitreal ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>40% Fluence Photodynamic Therapy Combined With Ranibizumab</title>
            <description>40% fluence photodynamic therapy combined with ranibizumab- procedure</description>
          </group>
          <group group_id="O3">
            <title>20% Fluence Photodynamic Therapy Combined With Ranibizumab</title>
            <description>20% fluence photodynamic therapy combined with ranibizumab- procedure</description>
          </group>
        </group_list>
        <measure>
          <title>OCT 3 Macular Thickness Improvement (Baseline-1month, 2months, 3months, 6months &amp;12 Months)</title>
          <description>OCT 3 macular thickness improvement at Baseline-1month, 2months, 3months, 6months &amp;12 months was not determined due to lack of efficacy.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Choroidal Perfusion as Assessed by ICG Angiography at 1, 2, 3, 6, and 12 Months</title>
        <description>Choroidal perfusion as assessed by ICG angiography at 1, 2, 3, 6, and 12 months was not determined due to lack of efficacy</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Only</title>
            <description>drug - intravitreal ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>40% Fluence Photodynamic Therapy Combined With Ranibizumab</title>
            <description>40% fluence photodynamic therapy combined with ranibizumab- procedure</description>
          </group>
          <group group_id="O3">
            <title>20% Fluence Photodynamic Therapy Combined With Ranibizumab</title>
            <description>20% fluence photodynamic therapy combined with ranibizumab- procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Choroidal Perfusion as Assessed by ICG Angiography at 1, 2, 3, 6, and 12 Months</title>
          <description>Choroidal perfusion as assessed by ICG angiography at 1, 2, 3, 6, and 12 months was not determined due to lack of efficacy</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Combination Therapy With Verteporfin PDT and ITV Ranibizumab</title>
        <description>Safety of combination therapy with verteporfin PDT and ITV ranibizumab was not determined due to lack of efficacy.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab Only</title>
            <description>drug - intravitreal ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>40% Fluence Photodynamic Therapy Combined With Ranibizumab</title>
            <description>40% fluence photodynamic therapy/combined with ranibizumab - procedure</description>
          </group>
          <group group_id="O3">
            <title>20% Fluence Photodynamic Therapy Combined With Ranibizumab</title>
            <description>20% fluence photodynamic therapy combined with ranibizumab - procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Combination Therapy With Verteporfin PDT and ITV Ranibizumab</title>
          <description>Safety of combination therapy with verteporfin PDT and ITV ranibizumab was not determined due to lack of efficacy.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab Only</title>
          <description>subject only received ranibizumab</description>
        </group>
        <group group_id="E2">
          <title>40% Fluence PDT Combined With Ranibizumab</title>
          <description>Subjects who have received 40% fluence PDT combined with as needed dosing with ranibizumab</description>
        </group>
        <group group_id="E3">
          <title>20% PDT Fluence Combined With Ranibizumab</title>
          <description>Subjects who received 20% with as needed ranibizumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Death of unknown origin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>1+ Nuclear Sclerosis</sub_title>
                <description>The cataract changes were found on a slip lamp/anterior chamber evaluation.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>2+ nuclear sclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was discontinued due to a lack of efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David M. Brown</name_or_title>
      <organization>Retina Consultants of Houston</organization>
      <phone>713-524-3434</phone>
      <email>dmbmd@houstonretina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

